New England Journal of Medicine
ISSN / EISSN : 0028-4793 / 1533-4406
Published by: Massachusetts Medical Society (10.1056)
Total articles ≅ 188,907
Latest articles in this journal
New England Journal of Medicine, Volume 385, pp 1539-1542; https://doi.org/10.1056/nejmp2108695
In the early months of 1968, the city of Memphis, Tennessee, witnessed a growing public outcry and a series of strikes organized by more than 1000 sanitation workers, the majority of whom were Black.1 Earlier that year, two employees — 36-year-old Echol Cole and 30-year-old Robert Walker — had been crushed to death in a garbage-truck compactor as they sought shelter from inclement weather, a practice that had become common after a citywide order prohibiting rest stations for sanitation workers in local neighborhoods. Long subjected to low wages and negligible employee protections, Memphis sanitation workers — and indeed, all essential but low-paid Black workers — soon gained international attention and became a focal point in the civil rights movement. Images of sanitation employees holding signs proclaiming “I Am a Man,” which laid bare the rampant discrimination that had denied workers their personhood and agency, would soon come to define the protests. To an audience of 25,000 people in a local Memphis church on March 18, 1968, Martin Luther King, Jr., offered both consolation and strength. “All labor has dignity,” he declared — an iconic line that has since bound conceptions of racial equity with those of economic and social justice.
New England Journal of Medicine, Volume 385; https://doi.org/10.1056/nejme2116820
The continuing spread of SARS-CoV-2 remains a Public Health Emergency of International Concern. What physicians need to know about transmission, diagnosis, and treatment of Covid-19 is the subject of ongoing updates from infectious disease experts at the Journal.
New England Journal of Medicine, Volume 385, pp 1632-1632; https://doi.org/10.1056/nejmx210010
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease (Original Article, N Engl J Med 2019;381:1103-1113). In the Secondary End Points subsection of Results (page 1108), a value given in the final sentence of the first paragraph was incorrect. The sentence should have read, “The most frequent causes of death were heart failure (6 patients in the monotherapy group and 10 in the combination-therapy group), stroke (2 vs. 9 patients), and cancer (6 vs. 13 patients),” rather than “… stroke (2 vs. 10 patients), and cancer (6 vs. 13 patients).” Table S7 in the Supplementary Appendix was also affected. The article is correct and the Supplementary Appendix has been replaced at NEJM.org.
New England Journal of Medicine, Volume 385, pp 1559-1569; https://doi.org/10.1056/nejmoa2029349
The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined.
New England Journal of Medicine, Volume 385; https://doi.org/10.1056/nejmicm2108779
An 82-year-old man presented to the emergency department with fever and confusion. Computed tomography of the abdomen showed gas in the liver, and a diagnosis of emphysematous hepatitis was made after cultures grew extended-spectrum beta-lactamase Klebsiella pneumoniae.
New England Journal of Medicine, Volume 385, pp 1631-1632; https://doi.org/10.1056/nejmc2113499
To the Editor: Zeiser et al. (July 15 issue)1 report a significantly better overall response in patients treated with ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease (GVHD), as they did 1 year ago for acute GVHD.2 The authors conclude that ruxolitinib was superior to control therapy, with no new safety signals. The data fail to convince. The authors describe chronic GVHD as “a leading cause…of nonrelapse-associated death.” However, overall survival did not differ substantially between the groups after half a year of treatment, with no fewer deaths from GVHD in the ruxolitinib group. Furthermore, the primary end point of overall response . . .
New England Journal of Medicine, Volume 385; https://doi.org/10.1056/nejmc2113564
To the Editor: Howell’s Perspective article (July 8 issue)1 did not mention the crucial pioneering contributions to computed tomographic (CT) scanning made by William H. Oldendorf,2 a fellow of the Institute of Electrical and Electronics Engineers and the first neurologist elected to the National Academy of Sciences.3 As a physician who performed pneumoencephalograms and carotid puncture angiography, Oldendorf searched for a more direct and humane way to image the brain. He was awarded the first patent for CT and produced the first known prototype apparatus in 1961,4 creating an image of an aluminum nail (“the tumor”) surrounded by iron nails . . .
New England Journal of Medicine, Volume 385, pp 1604-1613; https://doi.org/10.1056/nejmcpc2107351
A 14-year-old girl presented with progressive swelling of the jaw. Six weeks before this admission, a nonpainful lump in the left lower jaw developed. The mass increased in size, and swelling of the left side of the face and neck developed. A biopsy specimen from the mass showed abundant giant cells. The calcium level was 11.8 mg per deciliter. A diagnosis was made.
New England Journal of Medicine, Volume 385, pp 1547-1558; https://doi.org/10.1056/nejmoa2036205
Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.
New England Journal of Medicine, Volume 385; https://doi.org/10.1056/nejmc2113496
Rengasamy et al. address the administration of supplemental oxygen in their video and the associated print supplement (July 15 issue).1 We would like to emphasize the use of two techniques that allow improved oxygenation in nonintubated patients with hypoxemia.